Canada - English - Health Canada

searchlight pharma inc - estradiol; estradiol; norgestimate - tablet - 1mg; 1mg; 90mcg - estradiol 1mg; estradiol 1mg; norgestimate 90mcg - progestins

Canada - English - Health Canada

teva canada limited - arsenic trioxide - solution - 10mg - arsenic trioxide 10mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

kyowa kirin, inc. - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene 60 mg - fareston® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. fareston is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.7).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, fareston can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using fareston. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be appris

United States - English - NLM (National Library of Medicine)

advanced pharmaceutical technology, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 50 mg - estradiol is indicated in the treatment of: 1. estrogen deficiency in hysterectomized women. (there is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. atrophic vaginitis. 3. kraurosis vulvae. 4. female hypogonadism. 5. female castration. 6. primary ovarian failure. 7. breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. postpartum breast engorgement- althoughestrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies hve demonstrated that the incidence of significapainful engorgementin patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 estradiol has not been shown to be effective for any purpose durig pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women (or men) with any of the following conditions: 1. known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2. known or suspected estrogen-dependant neoplasia. 3. known or suspected pregnancy (see boxed warning). 4. undiagnosed abnormal genital bleeding. 5. active thrombophlebitis or thromboembolic disorders. 6. apast history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when used in treatment of breast prostatic malignancy).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - tamoxifen citrate -

Canada - English - Health Canada

teva canada limited - arsenic trioxide - solution - 10mg - arsenic trioxide 10mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - arsenic trioxide - solution - 12mg - arsenic trioxide 12mg - antineoplastic agents

Canada - English - Health Canada

phebra pty ltd - arsenic trioxide - solution - 10mg - arsenic trioxide 10mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; hypromellose; macrogol 4000; magnesium stearate; sodium starch glycollate - treatment of breast cancer. ? tamoxifen sandoz is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk ? tamoxifen sandoz is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamoxifen citrate, quantity: 15.2 mg (equivalent: tamoxifen, qty 10 mg) - tablet, film coated - excipient ingredients: hypromellose; povidone; lactose monohydrate; sodium starch glycollate; titanium dioxide; macrogol 4000; microcrystalline cellulose; magnesium stearate - treatment of breast cancer. ? tamoxifen sandoz is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk ? tamoxifen sandoz is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).